Cover Image
Market Research Report

Free Fatty Acid Receptor 1 - Pipeline Review, H1 2020

Published by Global Markets Direct Product code 358349
Published Content info 70 Pages
Delivery time: 1-2 business days
Price
Back to Top
Free Fatty Acid Receptor 1 - Pipeline Review, H1 2020
Published: April 30, 2020 Content info: 70 Pages
Description

Summary:

Free Fatty Acid Receptor 1 (G Protein Coupled Receptor 40 or GPR40 or FFAR1) pipeline Target constitutes close to 16 molecules. Out of which approximately 12 molecules are developed by companies and remaining by the universities/institutes. The latest report Free Fatty Acid Receptor 1 - Pipeline Review, H1 2020, outlays comprehensive information on the Free Fatty Acid Receptor 1 (G Protein Coupled Receptor 40 or GPR40 or FFAR1) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type.

Free Fatty Acid Receptor 1 (G Protein Coupled Receptor 40 or GPR40 or FFAR1) - Free fatty acid receptor 1 (FFA1), also known as GPR40, is a class A G-protein coupled receptor that is encoded by the FFAR1 gene. It is strongly expressed in the pancreatic islet cells and to a lesser extent in the brain. This membrane protein binds free fatty acids, acting as a nutrient sensor for regulating energy homeostasis. The molecules developed by companies in Phase III, Phase I and Preclinical stages are 1, 2 and 9 respectively. Similarly, the universities portfolio in Preclinical stages comprises 4 molecules, respectively. Report covers products from therapy areas Metabolic Disorders, Cardiovascular, Gastrointestinal, Genetic Disorders, Genito Urinary System And Sex Hormones, Infectious Disease, Oncology and Respiratory which include indications Type 2 Diabetes, Diabetes, Acute Lung Injury, Acute Renal Failure (ARF) (Acute Kidney Injury), Chronic Kidney Disease (Chronic Renal Failure), Hepatitis B, Idiopathic Pulmonary Fibrosis, Liver Cancer, Liver Fibrosis, Myocardial Fibrosis, Non Alcoholic Fatty Liver Disease (NAFLD), Non-Alcoholic Steatohepatitis (NASH) and Obesity.

Furthermore, this report also reviews key players involved in Free Fatty Acid Receptor 1 (G Protein Coupled Receptor 40 or GPR40 or FFAR1) targeted therapeutics development with respective active and dormant or discontinued projects. Driven by data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope:

  • The report provides a snapshot of the global therapeutic landscape for Free Fatty Acid Receptor 1 (G Protein Coupled Receptor 40 or GPR40 or FFAR1)
  • The report reviews Free Fatty Acid Receptor 1 (G Protein Coupled Receptor 40 or GPR40 or FFAR1) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved in Free Fatty Acid Receptor 1 (G Protein Coupled Receptor 40 or GPR40 or FFAR1) targeted therapeutics and enlists all their major and minor projects
  • The report assesses Free Fatty Acid Receptor 1 (G Protein Coupled Receptor 40 or GPR40 or FFAR1) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report summarizes all the dormant and discontinued pipeline projects
  • The report reviews latest news and deals related to Free Fatty Acid Receptor 1 (G Protein Coupled Receptor 40 or GPR40 or FFAR1) targeted therapeutics

Reasons to Buy:

  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand the targeted therapy areas and indications for Free Fatty Acid Receptor 1 (G Protein Coupled Receptor 40 or GPR40 or FFAR1)
  • Identify the use of drugs for target identification and drug repurposing
  • Identify potential new clients or partners in the target demographic
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding Free Fatty Acid Receptor 1 (G Protein Coupled Receptor 40 or GPR40 or FFAR1) development landscape
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
Table of Contents
Product Code: GMDHC2361TDB

Table of Contents

Table of Contents

List of Tables

List of Figures

  • Introduction
  • Global Markets Direct Report Coverage
  • Free Fatty Acid Receptor 1 (G Protein Coupled Receptor 40 or GPR40 or FFAR1) - Overview
  • Free Fatty Acid Receptor 1 (G Protein Coupled Receptor 40 or GPR40 or FFAR1) - Therapeutics Development
  • Products under Development by Stage of Development
  • Products under Development by Therapy Area
  • Products under Development by Indication
  • Products under Development by Companies
  • Products under Development by Universities/Institutes
  • Free Fatty Acid Receptor 1 (G Protein Coupled Receptor 40 or GPR40 or FFAR1) - Therapeutics Assessment
  • Assessment by Mechanism of Action
  • Assessment by Route of Administration
  • Assessment by Molecule Type
  • Free Fatty Acid Receptor 1 (G Protein Coupled Receptor 40 or GPR40 or FFAR1) - Companies Involved in Therapeutics Development
  • Amgen Inc
  • Cadila Healthcare Ltd
  • Caldan Therapeutics Ltd
  • Hyundai Pharma Co Ltd
  • Ildong Pharmaceutical Co Ltd
  • Johnson & Johnson
  • Liminal BioSciences Inc
  • Merck & Co Inc
  • Scohia Pharma Inc
  • Takeda Pharmaceutical Co Ltd
  • TiumBio Co Ltd
  • Free Fatty Acid Receptor 1 (G Protein Coupled Receptor 40 or GPR40 or FFAR1) - Drug Profiles
  • AM-3189 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • fasiglifam - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • HOB-047 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • IDG-16177 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • MK-2305 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • NCE-406 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • PBI-4050 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • SCO-267 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • Small Molecule to Agonize FFAR1 and PPARG for Type 2 Diabetes - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • Small Molecule to Agonize GPR40 for Type 2 Diabetes - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • Small Molecule to Agonize GPR40 for Type 2 Diabetes - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • Small Molecule to Agonize GPR40 for Type 2 Diabetes Mellitus - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • Small Molecules to Agonize GPR40 for Type 2 Diabetes - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • Small Molecules to Agonize PPAR Gamma and GPR40 for Diabetes - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • TUG-770 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • ZYDG-2 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • Free Fatty Acid Receptor 1 (G Protein Coupled Receptor 40 or GPR40 or FFAR1) - Dormant Products
  • Free Fatty Acid Receptor 1 (G Protein Coupled Receptor 40 or GPR40 or FFAR1) - Discontinued Products
  • Free Fatty Acid Receptor 1 (G Protein Coupled Receptor 40 or GPR40 or FFAR1) - Product Development Milestones
  • Featured News & Press Releases
  • Nov 18, 2019: Liminal presents new preclinical data on PBI-4050 and its effect on Angio-Proliferative Pulmonary Arterial Hypertension
  • Nov 12, 2019: Liminal BioSciences presents new preclinical data on PBI-4050
  • Nov 11, 2019: Liminal Biosciences presents new preclinical data on PBI-4050 at ASN Kidney Week 2019
  • Oct 25, 2019: Liminal BioSciences announces upcoming presentation on its liver disease drug candidate PBI-4050 at The Liver Meeting 2019
  • Oct 24, 2019: Liminal BioSciences announces upcoming presentation on drug candidate PBI-4050 at ASN kidney week 2019
  • Jun 14, 2019: Prometic presents new data on PBI-4050 and its mechanism of action on kidney fibrosis at the 56th ERA/EDTA Congress
  • Jun 11, 2019: Publication regarding a preclinical study of SCO-267, a novel GPR40 agonist
  • Jun 05, 2019: SCOHIA PHARMA to present new preclinical data of SCO267, a GPR40 agonist, at The American Diabetes Association's 79th Scientific Sessions
  • May 22, 2019: Prometic presents new PBI-4050 data on lung fibrosis at the 2019 ATS Conference
  • Dec 05, 2018: Prometic to initiate PBI-4050 pivotal phase 3 clinical trial in Alstrom Syndrome
  • Aug 10, 2018: Prometic announces the publication of PBI-4050's antifibrotic activity in liver diseases in journal of pharmacology and experimental therapeutics
  • Aug 07, 2018: Prometic receives rare pediatric disease designation from U.S. FDA for small molecule drug candidate PBI-4050
  • May 22, 2018: Prometic presents new clinical data on PBI-4050 for the treatment of idiopathic pulmonary fibrosis
  • Apr 12, 2018: Prometic Presents New PBI-4050 Clinical Data From Ongoing Alstrom Syndrome Phase 2 Trial
  • Mar 28, 2018: Prometic Reports Positive Clinical Data From Ongoing PBI-4050 Phase 2 Study in Alstrom Syndrome Patients
  • Appendix
  • Methodology
  • Coverage
  • Secondary Research
  • Primary Research
  • Expert Panel Validation
  • Contact Us
  • Disclaimer

List of Tables

  • Number of Products under Development by Stage of Development, H1 2020
  • Number of Products under Development by Therapy Areas, H1 2020
  • Number of Products under Development by Indication, H1 2020
  • Number of Products under Development by Companies, H1 2020
  • Products under Development by Companies, H1 2020
  • Products under Development by Companies, H1 2020 (Contd..1), H1 2020
  • Number of Products under Investigation by Universities/Institutes, H1 2020
  • Products under Investigation by Universities/Institutes, H1 2020
  • Number of Products by Stage and Mechanism of Actions, H1 2020
  • Number of Products by Stage and Route of Administration, H1 2020
  • Number of Products by Stage and Molecule Type, H1 2020
  • Pipeline by Amgen Inc, H1 2020
  • Pipeline by Cadila Healthcare Ltd, H1 2020
  • Pipeline by Caldan Therapeutics Ltd, H1 2020
  • Pipeline by Hyundai Pharma Co Ltd, H1 2020
  • Pipeline by Ildong Pharmaceutical Co Ltd, H1 2020
  • Pipeline by Johnson & Johnson, H1 2020
  • Pipeline by Liminal BioSciences Inc, H1 2020
  • Pipeline by Merck & Co Inc, H1 2020
  • Pipeline by Scohia Pharma Inc, H1 2020
  • Pipeline by Takeda Pharmaceutical Co Ltd, H1 2020
  • Pipeline by TiumBio Co Ltd, H1 2020
  • Dormant Products, H1 2020
  • Dormant Products, H1 2020 (Contd..1), H1 2020
  • Discontinued Products, H1 2020

List of Figures

  • Number of Products under Development by Stage of Development, H1 2020
  • Number of Products under Development by Therapy Areas, H1 2020
  • Number of Products under Development by Top 10 Indications, H1 2020
  • Number of Products by Stage and Mechanism of Actions, H1 2020
  • Number of Products by Stage and Route of Administration, H1 2020
  • Number of Products by Stage and Molecule Type, H1 2020
Back to Top